Status:
COMPLETED
Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Kidney Transplantation
Kidney Failure, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To compare the efficacy and safety of Tacrolimus in combination with MMF and Steroids in two regimens of steroid in an adult kidney transplanted population.
Eligibility Criteria
Inclusion
- Female subject of childbearing potential must have a negative serum pregnancy test at enrolment and must agree to maintain effective birth control during the study
- Has an end stage kidney disease and is a suitable candidate for primary renal transplantation or retransplantation
- Subject is receiving a kidney transplant, from a cadaveric or living donor between 5 and 65 years of age with compatible AB0 blood type
Exclusion
- Pregnant woman or breast-feeding mother
- Has an immunological high risk, defined as having a most recently measured PRA grade of \> 50% within the previous six months
- Known allergy to the study drug or any of its components
- Requires ongoing dosing with a systemic immunosuppressive drug at study entry for any reason other than kidney transplantation
- Requires initial sequential or parallel therapy with immunosuppressive antibody preparation(s)
- Subject or donor is known to be HIV positive
- Has significant liver disease, defined as having during the past 28 days continuously elevated ASAT (SGOT) and/or ALAT (SGPT) levels greater than 3 times the upper value of the normal range of the investigational site
- Diagnosis of malignancy or history of malignancy, except non metastatic basal or squamous cell carcinoma of the skin that has been treated successfully
- Has significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting, or active peptic ulcer
- Previously received or is receiving an organ transplant other than kidney
- Receiving a graft from a non-heart-beating donor
- Cold ischemia time of the donor kidney \>30 hours
- Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00717379
Start Date
May 1 2007
End Date
October 1 2008
Last Update
April 15 2009
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Moscow, Russia, 115446
2
Moscow, Russia, 119992
3
Moscow, Russia, 123182
4
Omsk, Russia, 644112